New Data on Vibecotamab, an AML Treatment

Xencor, a biopharmaceutical company that focuses on curating treatments for cancers and autoimmune conditions, has recently released data on vibecotamab. This acute myeloid leukemia treatment was included in a Phase 1 trial, in which preliminary data is positive.

About Acute Myeloid Leukemia (AML)

AML is a blood and bone marrow cancer. The bone marrow makes abnormal blood cells which then crowd and get rid of healthy blood cells. This leads to symptoms like easy bruising, frequent infections, lethargy, fatigue, bone pain, fever, pale skin, shortness of breath, and unusual bleeding. Mutations in the DNA lead to this cancer, although medical professionals are unsure as to how these mutations occur. One can also develop this disease from MDS, aplastic anemia, or a myeloproliferative disorder. When this is the case, it is called secondary AML. Treatment consists of remission induction therapy, chemotherapy, drug therapy, or a stem cell transplant.

About Vibecotamab

Vibecotamab is an antibody that targets tumors and contains CD123 binding domain and a cytotoxic T-cell binding domain. It has been indicated as a treatment for AML and other hematologic malignancies that express CD123.

Phase 1 Data

Data from this trial was presented at 62nd ASH Annual Meeting, and it has been positive so far. Vibecotamab has shown clinically meaningful activity, with some patients reaching complete responses. While cytokine release syndrome (CRS) has been named as the primary toxicity of this treatment, any reactions have been mild to moderate, and researchers have worked to mitigate its effects.

112 participants had been dosed at the time of the data collection, and more are being enrolled in this ongoing trial. The median age of these patients was 64, and they had already received a median of three prior treatments. Results include:

  • 61% of patients experienced CRS
    • 9% experienced CRS at Grade 3 or higher
  • 2 participants reached complete remission
  • 3 participants reached complete remission without complete hematologic recovery
  • One participant reached partial remission
  • Overall response rate was 15%

Researchers are excited by these results and will continue to develop vibecotamab for the treatment of acute myeloid leukemia.

Click here for the source article.

Share this post